Viral infections Hep C and HIV linked to hip fractures
|
|
- Alaina Hines
- 5 years ago
- Views:
Transcription
1 CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Viral infections Hep C and HIV linked to hip fractures 22 November 2012 Infection with hepatitis C virus (HCV) and HIV causes inflammation, a natural response by the immune system as it seeks to deal with invading germs. However, sometimes the sheer number of germs overwhelms the immune system or at other times the germs are able to subvert the immune system s response to infection. In such cases, the germs spread and infection takes hold. This can be the case with viral infections and when such an infection becomes established in the body, it becomes a chronic infection. Even in cases of chronic viral infections the immune system tries to fight the infection, but inflammation that may have been useful in the initial stages of exposure becomes a problem if it is sustained over the long-term. The immune system and its cells are widely distributed throughout the body and found within many organ-systems such as the following: brain bones cardiovascular system liver lungs kidneys A chronic viral infection with its associated inflammation of the immune system is likely to cause inflammation-related problems for these organ-systems. HCV and bones The inflammation caused by chronic HCV infection affects the liver, causing this organ to become dysfunctional and injured. HCV can also cause other problems; for instance, some studies have found thinner-than-normal bones in some HCV-positive people. Some researchers think that this problem of bone thinning in HCV infection arises in part because of complications of liver injury and chronic liver inflammation. An injured and inflamed liver could result in reduced levels of the hormones estrogen and testosterone. These hormones play an important role in maintaining the health of bones. Also, a dysfunctional liver may not be able to convert vitamin D to its active form. This may affect the body s ability to absorb and retain nutrients such as calcium and phosphorus, which are needed to build bones. HIV and bones Potent combination anti-hiv therapy (commonly called ART or HAART) can also temporarily decrease the thickness of bones (called bone mineral density) in the first few years of use. However, after this, bone mineral density tends to stabilize. The reason for the initially decreased bone mineral density under ART is not yet clear. But the benefits of ART continue to greatly outweigh the risks. Focus on the hips A team of researchers in the U.S. has grown concerned about the strength of bones in the hips of people with HCV,
2 HIV or both viral infections. Among HIV-negative people, when hip bones/joints become broken their survival subsequently decreases. Moreover, the U.S. researchers noted: Hip fractures cause significant pain and disability and typically require an emergency department visit, hospitalization, surgery and rehabilitation stay, resulting in substantial healthcare costs. The U.S. research team (based at the University of Pennsylvania) conducted a massive study of three million people, both with and without different viral infections. They found that people co-infected with HIV and HCV were at greatest risk of hip fracture compared to participants with HCV infection alone (monoinfection) or to people who had neither infection. This study underscores the need to understand why thinning bones, particularly in the hips, occur in people with HIV, HCV or both. Furthermore, ways to improve the bone health of people with chronic viral infections are needed. Study details Researchers at hospitals in Philadelphia and Boston collaborated on a massive cohort study, analysing health relatedinformation collected from adults using the U.S. Medicaid program in the following states: California Florida New York Ohio Pennsylvania The research team compared data assembled on each person with HCV monoinfection, HIV monoinfection and both infections (co-infection) and compared them to health-related data collected from up to 10 randomly selected people without viral infections. The researchers analysed data collected from more than three million people distributed as follows: HCV monoinfection 276,901 participants HIV monoinfection 95,827 participants HIV-HCV co-infection 36,950 participants uninfected people 2,744,075 participants On average, participants were in their early 40s, and 60% were men and 40% women. They were monitored for up to seven years. Results Other conditions and medicines The study team found that it was relatively common for HCV-positive people to have been diagnosed with conditions that were either associated with severely thin bones (osteoporosis) or a risk of falling, including the following: alcoholism asthma cardiovascular disease type II diabetes kidney disease excessive levels of parathyroid hormone rheumatoid arthritis They also found that participants with HCV monoinfection were more likely than other groups in the study to have received medicines associated with thinning bones, including the following drugs: corticosteroids a group of acid-reducing agents called proton pump inhibitors Results Comparing fracture risks between people with and without HCV
3 Overall, HCV-positive people had a 47% increased risk of hip fracture compared to uninfected people. However, it is important to note that this risk varied, in some cases, by factors such as age and gender among HCV-positive people, as follows: Age more than 70 years No increased risk of hip fractures due to HCV monoinfection were seen. Age less than 70 years There was an increased risk for hip fracture due to HCV monoinfection. Age 18 to 39 years There was nearly a four-fold increased risk for hip fracture among women and slightly more than a two-fold increased risk for men. Results Comparing fracture risks between co-infected and uninfected people Overall, ART-treated participants had a greater risk for hip fracture (about two-fold) compared to uninfected people. In general, for co-infected men and women fracture risk rose with age. Results Comparing fracture risks between co-infected people and people with HIV monoinfection Overall, ART-using co-infected participants had a greater risk for hip fracture than ART-using participants with HIV monoinfection. This increased risk differed by gender, with co-infected ART-using women having a 76% increased risk and co-infected ART-using men having a 36% increased risk for hip fracture. Results Comparing fracture risks between co-infected people and people with HCV monoinfection Among all HIV-HCV co-infected people, there was a 38% increased risk for hip fracture compared to HCVmonoinfected people. Key findings 1. HIV-HCV co-infected people who use ART have increased risk for hip fractures compared to the following groups of people: HCV monoinfection HIV moninfection + use of ART people who have neither HIV nor HCV 2. HCV-monoinfected people have increased risk for hip fracture compared to people without HCV (or HIV) who are under the age of 70. Viral infections and bones Researchers are not certain why there was an increased risk for hip fractures among HCV-positive people. We have already mentioned the potential impact of chronic inflammation and liver injury on bone health. However, more research needs to be done to fully understand the general impact of chronic HCV infection on bone health. Other factors that could have affected bone health The research team noted that certain factors that are relatively common among some HCV-positive people could also play a role in the loss of bone mineral density, including the following:
4 use of street drugs smoking excessive intake of alcohol poor nutrition length of time infected with HCV or HIV Their data set did not include these missing factors and that is one weakness that may have affected the study s conclusions. Focus on HIV and its treatment Other studies have found that HIV-positive people (and even some people at high risk for HIV infection) tend to have reduced bone mineral density. The reason(s) for this are not clear. Chronic HIV infection also causes inflammation that is only partially reduced with treatment. Less-than-optimal levels of vitamin D are also relatively common in HIVpositive people. Deficiencies of testosterone, reduced muscle mass and perhaps other factors could play a role in thinning bones as well. The researchers attempted to assess the impact on bone health of anti-hiv drugs that were prescribed for participants initial treatment. However, due to built-in limitations of the study s retrospective design, researchers cannot draw firm conclusions about the long-term impact of such drugs on the risk of hip fracture. Size and strengths The study is unusual because of its immense size, and this is a great strength. That the researchers compared different groups of people with and without different viral infections is another strength. The study s findings are generally sound there is an increased risk for hip fractures among people with HCV infection, including people who are co-infected with HCV and HIV. A previous French study has also found an increased risk for fractures among co-infected people. Now other research teams need to investigate precisely why HCV is associated with reduced bone mineral density and explore interventions that can improve bone health in people with HCV monoinfection as well as those with HCV- HIV co-infection. Resources: TreatmentUpdate 189 issues related to bone health Boning up on bone health The Positive Side Good to the bone The Positive Side Osteoporosis Canada REFERENCES: Sean R. Hosein 1. Lo Re V 3rd, Volk J, Newcomb CW, et al. Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection. Hepatology Nov;56(5): Li Vecchi V, Soresi M, Giannitrapani L, et al. Dairy calcium intake and lifestyle risk factors for bone loss in HIVinfected and uninfected Mediterranean subjects. BMC Infectious Diseases Aug 15;12: Walker Harris V, Sutcliffe CG, et al. Hip bone geometry in HIV/HCV-co-infected men and healthy controls. Osteoporosis International Jun;23(6): Collin F, Duval X, Le Moing V, et al. Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS May 15;23(8): Grijsen ML, Vrouenraets SM, Wit FW, et al. Low bone mineral density in men who have sex with men regardless of HIV status. Journal of Infectious Diseases. 2012; in press.
5 Produced By: 555 Richmond Street West, Suite 505, Box 1104 Toronto, Ontario M5V 3B1 Canada Phone: Toll-free: Fax: Charitable registration number: RR Disclaimer Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner knowledgeable about HIV- and hepatitis C-related illness and the treatments in question. CATIE provides information resources to help people living with HIV and/or hepatitis C who wish to manage their own health care in partnership with their care providers. Information accessed through or published or provided by CATIE, however, is not to be considered medical advice. We do not recommend or advocate particular treatments and we urge users to consult as broad a range of sources as possible. We strongly urge users to consult with a qualified medical practitioner prior to undertaking any decision, use or action of a medical nature. CATIE endeavours to provide the most up-to-date and accurate information at the time of publication. However, information changes and users are encouraged to ensure they have the most current information. Users relying solely on this information do so entirely at their own risk. Neither CATIE nor any of its partners or funders, nor any of their employees, directors, officers or volunteers may be held liable for damages of any kind that may result from the use or misuse of any such information. Any opinions expressed herein or in any article or publication accessed or published or provided by CATIE may not reflect the policies or opinions of CATIE or any partners or funders. Information on safer drug use is presented as a public health service to help people make healthier choices to reduce the spread of HIV, viral hepatitis and other infections. It is not intended to encourage or promote the use or possession of illegal drugs. Permission to Reproduce This document is copyrighted. It may be reprinted and distributed in its entirety for non-commercial purposes without prior permission, but permission must be obtained to edit its content. The following credit must appear on any reprint: This information was provided by CATIE (the Canadian AIDS Treatment Information Exchange). For more information, contact CATIE at CATIE Production of this content has been made possible through a financial contribution from the Public Health Agency of Canada. Available online at:
From Safer Sex Guide. Using condoms
From Safer Sex Guide Using condoms Click to enlarge Using condoms correctly and consistently can signifiantly reduce your chances of passing or getting HIV and other STIs. There are two types of condoms
More informationLong-acting drugs for HIV
From TreatmentUpdate 222 Long-acting drugs for HIV Long-acting formulations of two anti-hiv drugs are being tested in clinical trials: cabotegravir an experimental integrase inhibitor made available in
More informationUnderstanding risk by sex act
From Safer Sex Guide Understanding risk by sex act Kissing (with tongue) Chlamydia Avoid kissing if you or your partners have sores on the lips or mouth, or if one of you has an active oral infection (such
More informationA study about switching from TDF to TAF
From TreatmentUpdate 211 A study about switching from TDF to TAF Researchers enrolled HIV-positive participants who were taking regimens containing TDF (tenofovir disoproxil fumarate), the original formulation
More informationNorthern Alberta preventing HIV transmission to babies
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Northern Alberta preventing HIV transmission to babies 25 June 2009 Since 1996 the widespread availability of combination therapy for HIV
More informationDoravirine vs. darunavir
From TreatmentUpdate 220 Doravirine vs. darunavir Doravirine is an experimental non-nuke that is undergoing phase III clinical trials. It is designed to be effective against most strains of HIV that are
More informationDetailed results from the START study
From TreatmentUpdate 210 Detailed results from the START study Researchers in 35 countries across all continents collaborated to recruit 4,685 HIV-positive adults who were in good health for START. Upon
More informationPatient navigators for hepatitis C patients found useful in New York City
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Patient navigators for hepatitis C patients found useful in New York City 4 January 2017 Hepatitis C virus (HCV) infects and injures the
More informationExploring the risks of liver cancer after successful treatment for hepatitis C virus
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Exploring the risks of liver cancer after successful treatment for hepatitis C virus 11 June 2013 In Canada and other high-income countries,
More informationThe debut of velpatasvir for hepatitis C
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. The debut of velpatasvir for hepatitis C 23 November 2015 Hepatitis C virus (HCV) can be grouped into six major strains, or genotypes,
More informationStudy finds PEP not 100% effective in preventing HIV infection
From TreatmentUpdate 152 Study finds PEP not 100% effective in preventing HIV infection Some doctors and nurses who care for PHAs may sustain needle-stick injuries. This raises the possibility that they
More informationHepatitis C treatment program improves access to housing, income and healthcare
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Hepatitis C treatment program improves access to housing, income and healthcare 13 July 2015 Despite high rates of hepatitis C virus (HCV)
More informationHere are some of the steps (greatly simplified) and gaps that can occur in the HIV Treatment Cascade:
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Alberta Reducing deaths by strengthening the HIV Treatment Cascade 20 May 2014 In Canada and other high-income countries, deaths from AIDS-related
More informationHow are testing technologies used to diagnose HIV infection?
HIV testing technologies are used to determine if a person has HIV. Several types of HIV testing technologies are used in Canada. These tests differ in several ways, including where the test is conducted,
More informationNorwegian HIV vaccine Very modest results seen in recent clinical trial
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Norwegian HIV vaccine Very modest results seen in recent clinical trial 21 February 2012 Although HIV infection can be treated with combination
More informationStudy finds sustained-release dexamfetamine is promising for reducing cocaine use
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Study finds sustained-release dexamfetamine is promising for reducing cocaine use 27 April 2016 Depending on the circumstances, the use
More informationLimiting the spread of hepatitis C virus with Treatment as Prevention (TasP)
From TreatmentUpdate 197 Limiting the spread of hepatitis C virus with Treatment as Prevention (TasP) The idea of Treatment as Prevention, or TasP, has been proposed and is being implemented in some regions
More informationThe epidemiology of HIV in Canada
FACTSHEET The epidemiology of HIV in Canada This fact sheet provides a snapshot of the HIV epidemic in Canada. It is one of a series of fact sheets on the epidemiology of HIV and hepatitis C in Canada.
More informationThe epidemiology of hepatitis C in Canada
The epidemiology of hepatitis C in Canada FACT SHEET Published 2017 This fact sheet provides a snapshot of the hepatitis C epidemic in Canada. It is one of a series of fact sheets providing epidemiological
More informationIs there a link between niacin and stroke?
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Is there a link between niacin and stroke? 7 July 2011 A large American-Canadian study called Aim-High was halted 18 months ahead of schedule.
More informationHIV and the immune system linked to heart disease in women
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. HIV and the immune system linked to heart disease in women 26 September 2013 The widespread availability of potent combination anti-hiv
More informationStudy explores risk for shingles in the current era
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Study explores risk for shingles in the current era 19 February 2015 Infection with VZV (varicella zoster virus), a member of the herpes
More informationIncreased risk for dialysis found with HIV infection
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Increased risk for dialysis found with HIV infection 12 September 2013 In high-income countries such as Canada, Australia and the U.S.
More informationHIV testing technologies
HIV testing technologies HIV testing technologies are used to determine if a person has HIV. Several types of HIV testing technologies are used in Canada. These tests differ in several ways, including
More informationHep C treatment can cure a person from Hep C. However, a person could get infected again.
Sofosbuvir (Sovaldi) Summary Sofosbuvir is a medication used to treat Hep C. It is used in combination with other medications to cure people of the Hep C virus. Sofosbuvir is taken at a dose of 400 mg
More informationKey messages on hepatitis A for clients are available at the end of this fact sheet.
Hepatitis A Summary Hepatitis A is an infection caused by a virus that can be sexually transmitted. Infection with hepatitis A results in inflammation of the liver (hepatitis). Hepatitis A is transmitted
More informationDoes tenofovir (TDF) cause liver injury?
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Does tenofovir (TDF) cause liver injury? 10 February 2016 Tenofovir is an important antiviral drug used to treat HIV and hepatitis B virus
More informationPost-exposure prophylaxis (PEP)
Post-exposure prophylaxis (PEP) Summary Post-exposure prophylaxis, or PEP, is a way to help prevent the transmission of HIV in an HIV-negative person who may have been recently exposed to HIV. It involves
More informationHepatitis A FACTSHEET. Summary. What is hepatitis A?
FACTSHEET Hepatitis A Summary Hepatitis A is an infection caused by a virus that can be sexually transmitted. Infection with hepatitis A results in inflammation of the liver (hepatitis). Hepatitis A is
More informationAmerican Academy of Pediatrics issues statement on infant feeding and HIV transmission
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. American Academy of Pediatrics issues statement on infant feeding and HIV transmission 7 February 2013 The widespread availability of potent
More informationDoes syphilis affect HIV in the brain?
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Does syphilis affect HIV in the brain? 1 February 2011 Outbreaks of sexually transmitted infections (STIs) are occurring in Canada and
More informationSuperbug increasing among HIV positive people
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Superbug increasing among HIV positive people 24 September 2007 Bacteria are a common source of problems, causing a variety of infections,
More informationQuad (Stribild) Safety and effectiveness issues in depth
From TreatmentUpdate 191 Quad (Stribild) Safety and effectiveness issues in depth The FDA reviewed health-related information collected from 1,408 HIV-positive people who participated in two pivotal clinical
More informationHepatitis C Basics. Michael Bailey Director of Programming, CATIE. Mary Choy Regional Health Education Coordinator, CATIE
Hepatitis C Basics Michael Bailey Director of Programming, CATIE Mary Choy Regional Health Education Coordinator, CATIE CATIE Our History Learning Objectives 1) To learn about the basics of hepatitis C
More informationCan metformin also protect arteries?
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Can metformin also protect arteries? 8 December 2011 Reports suggest that cardiovascular disease is becoming common among HIV-positive
More informationStarting points. living with HIV
Starting points living with HIV Have you found out you have HIV and are trying to get your bearings? We can help you with the basics of living with HIV. Here s what you ll read about in this booklet: What
More informationIt is a good idea for anyone having sex to get tested regularly and treated for STIs if necessary.
FACTSHEET Sexually Transmitted Infections and HIV Transmission This is one of a series of fact sheets about the biology of HIV transmission. The fact sheets review specific biological factors that make
More informationHepatitis C virus some background information
From TreatmentUpdate 167 Hepatitis C virus some background information Hepatitis C virus (HCV) is spread by exposure to infected blood. The following behaviours, which can expose a person to infected blood,
More informationTHE POWER OF UNDETECTABLE. What you need to know about HIV treatment as prevention
THE POWER OF UNDETECTABLE What you need to know about HIV treatment as prevention CONTENTS 3 Treatment as prevention First, a few basics: What is an undetectable viral load? How do I know if I m undetectable?
More informationExploring risks for MRSA infection A tale of two studies
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Exploring risks for MRSA infection A tale of two studies 2 March 2012 A group of bacteria called S. aureus (Staphylococcus aureus ) are
More informationThe Patient as Partner
From The Positive Side, Summer 2018 The Patient as Partner The idea that a person should be an active participant, not just a recipient, of their own healthcare has deep roots. Feminists, people living
More informationRaltegravir (Isentress)
Raltegravir (Isentress) Summary Raltegravir is a type of anti-hiv drug called an integrase inhibitor. Raltegravir is generally well tolerated. Common side effects include diarrhea, nausea and headache;
More informationExciting results in monkeys lead to a clinical trial in humans
From TreatmentUpdate 219 Exciting results in monkeys lead to a clinical trial in humans A close relative of HIV called SIV (simian immunodeficiency virus) causes an AIDS-like disease in susceptible monkeys.
More informationPre-exposure prophylaxis (PrEP)
FACTSHEET Pre-exposure prophylaxis (PrEP) Summary Pre-exposure prophylaxis, or PrEP, is a way for an HIV-negative person who is at risk of HIV infection to reduce their risk of becoming infected with HIV.
More informationCan mirtazapine assist recovery from crystal meth addiction?
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Can mirtazapine assist recovery from crystal meth addiction? 20 December 2011 Stimulants such as amphetamine and its more potent form,
More informationProgramming Connection
The H.E.R. Pregnancy Program Programming Connection Case Study Organization: Streetworks Region: Edmonton, Alberta Prepared: 2018 Quick Facts Population Street involved, Women Date Started 2011 Region
More information3TC (lamivudine, Epivir)
3TC (lamivudine, Epivir) Summary 3TC is a type of antiretroviral drug called a nucleoside analogue (or nuke ). 3TC can cause nausea, headache, diarrhea, vomiting and weakness; however, it causes few side
More informationHarvoni (ledipasvir + sofosbuvir)
FACTSHEET Harvoni (ledipasvir + sofosbuvir) Summary Harvoni is a medication used to treat hepatitis C. It is approved in Canada for people with genotype 1 hepatitis C virus. Harvoni is a combination of
More informationTreatment Bulletin. Aging & HIV. Toronto People With AIDS Foundation. A comprehensive guide to aging for people living with HIV/AIDS.
Toronto People With AIDS Foundation Treatment Bulletin Aging & HIV February 2010 Disclaimer The Treatment Resources Program at the Toronto People With AIDS Foundation provides information and resources
More informationHarvoni (ledipasvir + sofosbuvir)
Harvoni (ledipasvir + sofosbuvir) Summary Harvoni is a medication used to treat hepatitis C. It is approved in Canada for people with all genotypes of the hepatitis C virus. Harvoni is a combination of
More informationMG an emerging sexually transmitted infection
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. MG an emerging sexually transmitted infection 9 October 2013 The bacterium Mycoplasma genitalium (MG) is sexually transmitted and can cause
More informationIMPORTANT THINGS TO KNOW WHEN YOU HAVE HEPATITIS C
IMPORTANT THINGS TO KNOW WHEN YOU HAVE HEPATITIS C GETTING STARTED: Important things to know when you have hepatitis C If you just found out that you have hepatitis C, you may have a lot of questions.
More informationSchizophrenia and HIV Study underscores serious issues associated with dual diagnoses
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Schizophrenia and HIV Study underscores serious issues associated with dual diagnoses 15 July 2015 Several studies have found that some
More informationDaclatasvir (Daklinza)
Daclatasvir (Daklinza) Summary Daclatasvir (Daklinza) is a medication used to treat hepatitis C. It is taken with sofosbuvir (Sovaldi) and sometimes ribavirin. This combination is approved in Canada for
More informationI ANTI-HIV AGENTS. Contents I ANTI-HIV AGENTS II COMPLICATIONS AND SIDE EFFECTS. A. Raltegravir vs. efavirenz four. years later
TreatmentUpdate 179 Vol. 22, No. 4 May/June 2010 ISSN 11817187 Available on the World Wide Web at www.catie.ca/tu.nsf Contents I ANTI-HIV AGENTS A. Raltegravir vs. efavirenz four years later 1 B. Raltegravir
More informationLymphoma FACTSHEET. Summary. About the lymphatic system. Who is at risk for lymphoma? What is lymphoma?
FACTSHEET Lymphoma Summary Lymphoma is a cancer that affects a part of the immune system called the lymphatic system. Like any cancer, the earlier lymphoma is diagnosed, the easier it is to treat. In general,
More informationWill de-simplification of HIV treatment become common in highincome
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Will de-simplification of HIV treatment become common in highincome countries? 13 February 2018 As more people start HIV treatment, researchers
More information3TC (lamivudine, Epivir)
FACTSHEET 3TC (lamivudine, Epivir) Summary 3TC is a type of antiretroviral drug called a nucleoside analogue (or nuke ). 3TC can cause nausea, headache, diarrhea, vomiting and weakness; however, it causes
More informationCrystal meth interviews reveal its impact on HIV positive men
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Crystal meth interviews reveal its impact on HIV positive men 15 April 2009 Crystal meth, also known as ice or Tina, is a form of the stimulant
More informationThe elusive AIDS vaccine
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. The elusive AIDS vaccine 4 March 2008 In the 25 years since HIV was discovered, researchers have made many strides in the fight against
More informationDaclatasvir (Daklinza)
FACTSHEET Daclatasvir (Daklinza) Summary Daclatasvir (Daklinza) is a medication used to treat hepatitis C. It is taken with sofosbuvir (Sovaldi) and sometimes ribavirin. This combination is approved in
More informationRibavirin (Ibavyr, Moderiba)
Ribavirin (Ibavyr, Moderiba) Summary Ribavirin is a medication used to treat hepatitis C. It is used in combination with other medications to cure people of the hepatitis C virus. Ribavirin is taken orally
More informationTuberculosis FACT SHEET. Summary. What is TB?
Tuberculosis Summary Tuberculosis (TB) is caused by bacteria called Mycobacterium tuberculosis complex and usually affects the lungs. However, among people co-infected with TB and HIV, parts of the body
More informationHPV, Cervical Dysplasia and Cancer
FACTSHEET HPV, Cervical Dysplasia and Cancer Summary Cervical dysplasia is an abnormal change in the cells of the cervix in the uterus. Early changes, called low-grade lesions by doctors, may persist and
More informationThe HIV testing process
FACTSHEET The HIV testing process Summary There are a few steps that a person will take in the HIV testing process. To access an HIV test, people can request a test or may be offered a test. There are
More informationTuberculosis FACTSHEET. Summary. What is TB?
FACTSHEET Tuberculosis Summary Tuberculosis (TB) is caused by bacteria called Mycobacterium tuberculosis complex and usually affects the lungs. However, among people co-infected with TB and HIV, parts
More informationOsteoporosis The Silent Disease
Joel Johnson, Yr, Subtask, Biology ER., 7/9/5 Osteoporosis The Silent Disease What is Osteoporosis? Osteoporosis is a disease which causes bones to become brittle, which increases the risk of broken bones.
More informationAsk the Experts: Managing Lipid Levels
From The Positive Side, Winter 2013 Ask the Experts: Managing Lipid Levels My doctor said that my lipid levels are cause for concern. Any do s and don ts you can share? JB, Brandon, Manitoba Interviews
More informationSome research issues with marijuana, HIV and inflammation
From TreatmentUpdate 225 Some research issues with marijuana, HIV and inflammation The body produces many compounds that cells use to send information via signals to each other. One such system of signals
More informationDescovy FACTSHEET. Summary. What is Descovy? How does Descovy work?
FACTSHEET Descovy Summary Descovy is the name given to a pill containing the following two anti- HIV drugs: TAF (tenofovir alafenamide) and FTC (emtricitabine). Descovy comes in two, colour-coded strengths
More informationRaltegravir (Isentress)
FACTSHEET Raltegravir (Isentress) Summary Raltegravir is a type of anti-hiv drug called an integrase inhibitor. Common side effects of raltegravir include diarrhea, nausea and headache; these are usually
More informationRibavirin (Copegus, Ibavyr, Moderiba)
FACTSHEET Ribavirin (Copegus, Ibavyr, Moderiba) Summary Ribavirin is a medication used to treat hepatitis C. It is used in combination with other medications to cure people of the hepatitis C virus. Ribavirin
More informationToxoplasmosis FACT SHEET. What is toxoplasmosis? Symptoms CONTACT US. Published 2016
Toxoplasmosis What is toxoplasmosis? Toxoplasmosis is an infection caused by the parasite Toxoplasma gondii (T. gondii). The parasite is transmitted to people through eating undercooked meat, especially
More informationOsteoporosis and Fracture: Prevention in the Long Term Care Setting Clinical Practice Guideline. Continuing Professional Education Self-Study Course
Osteoporosis and Fracture: Prevention in the Long Term Care Setting Clinical Practice Guideline Continuing Professional Education Self-Study Course Written by Liz Friedrich, MPH, RD, CSG, LDN, FAND Edited
More informationHints of a cure the future of stem cell transplants and HIV
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Hints of a cure the future of stem cell transplants and HIV 21 December 2010 In 2008 a team of cancer researchers from Berlin, Germany,
More informationFACTSHEET. Women and the Biology of HIV Transmission
FACTSHEET Women and the Biology of HIV Transmission The majority of HIV infections are transmitted sexually and so most of the transmission occurs through the genital or reproductive systems of men and
More informationHIV and your Bones Osteopenia and Osteoporosis
Osteopenia and Osteoporosis Background information For reasons not yet fully understood, higher rates of bone disease are starting to be seen in people living with HIV. These bone diseases include osteopenia
More informationPossible roles for vitamin D in selected infections TB, colds and flu, HIV, hepatitis C virus and bacterial vaginosis
From TreatmentUpdate 185 Possible roles for vitamin D in selected infections TB, colds and flu, HIV, hepatitis C virus and bacterial vaginosis Lab experiments with cells of the immune system monocytes
More informationHelpful information about bone health & osteoporosis Patient Resource
Helpful information about bone health & osteoporosis Patient Resource Every year In the United States, 2.5 million fractures occur due to osteoporosis. Out of these, 330,000 are hip fractures, and half
More informationd4t (stavudine, Zerit)
d4t (stavudine, Zerit) Summary d4t (stavudine, Zerit) is a type of anti-hiv drug called a nuke or nucleoside analogue. Common side effects of d4t can include headache, nausea, vomiting and diarrhea. d4t
More informationKey messages on chlamydia for clients are available at the end of this fact sheet.
Chlamydia Summary Chlamydia is a sexually transmitted infection caused by a bacterium. It can be transmitted through sexual contact. All people who are sexually active may be at risk for chlamydia. Chlamydia
More informationLearning Objectives. ! Students will become familiar with the 3 treatment solutions for osteoporosis. ! Students should be able to define osteoporosis
Learning Objectives! Students should be able to define osteoporosis! Students should be able to identify some risk factors of osteoporosis! Students should be able to identify some of the people in the
More informationMe and My Liver. Liver Lessons. From The Positive Side, Spring/Summer A cautionary tale about chemical hepatitis. By Gregory Robinson
From The Positive Side, Spring/Summer 2005 Me and My Liver A cautionary tale about chemical hepatitis By Gregory Robinson JANUARY 2002. My year got off to a rocky start. I glanced up at the doctor from
More informationHPV, anal dysplasia and anal cancer
HPV, anal dysplasia and anal cancer Summary Anal cancer typically develops over a period of years, beginning with a precancerous condition called anal dysplasia. Anal dysplasia occurs when clusters of
More informationHPV, cervical dysplasia and cervical cancer
HPV, cervical dysplasia and cervical cancer FACT SHEET Published 2016 Summary Cervical dysplasia is an abnormal change in the cells of the cervix in the uterus. Early changes, called low-grade lesions
More informationLymph nodes reveal HIV s hiding place scientists call for new
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Lymph nodes reveal HIV s hiding place scientists call for new drugs 13 February 2014 Potent combination HIV therapy (commonly called ART
More informationA JOINT INITIATIVE FOR FRACTURE PREVENTION. Know Your Bones Community Risk Report October 2018
A JOINT INITIATIVE FOR FRACTURE PREVENTION Forewords Greg Lyubomirsky CEO Osteoporosis Australia 1 Know Your Bones was developed to help Australians understand their risk of poor bone health and discuss
More informationHIV treatment and an undetectable viral load to prevent HIV transmission
HIV treatment and an undetectable viral load to prevent HIV transmission FACT SHEET Published 2018 CONTACT US Summary It is now well known that the use of HIV treatment not only improves the health of
More informationA Patient s Guide to Nutraceuticals (Dietary Supplements)
A Patient s Guide to Nutraceuticals (Dietary Supplements) 2350 Royal Boulevard Suite 200 Elgin, IL 60123 Phone: 847.931.5300 Fax: 847.931.9072 DISCLAIMER: The information in this booklet is compiled from
More informationFacts About Aging and. Bone Health. A Guide to Better Understanding and Well-Being. This educational information is proudly provided by
and Bone Health A Guide to Better Understanding and Well-Being This educational information is proudly provided by Aging The fact is, everyone experiences slow loss of bone strength and bone density throughout
More informationParathyroid Hormone: An Expert Consultation
Parathyroid Hormone: An Expert Consultation Health Quality Ontario July 2013 Parathyroid Hormone: An Expert Consultation. July 2013; pp. 1 11. Suggested Citation This report should be cited as follows:
More informationHepatitis B FACTSHEET. Summary
FACTSHEET Hepatitis B Summary Hepatitis B is an infection caused by a virus that can be transmitted by sexual exposure to blood or bodily fluids, injection drug use, and household contact with someone
More informationRaltegravir (Isentress)
FACTSHEET Raltegravir (Isentress) Summary Raltegravir is a type of anti-hiv drug called an integrase inhibitor. Common side effects of raltegravir include diarrhea, nausea and headache. The dose of raltegravir
More informationArt Posi+ive: The Best of Both Worlds
From The Positive Side, Summer 2017 Art Posi+ive: The Best of Both Worlds Tradition meets innovation in the work of William Flett. By Darien Taylor Killer Whale One of William Flett s earliest childhood
More informationAntiviral medications can reduce the severity and frequency of genital herpes outbreaks.
Genital herpes Summary Genital herpes is a sexually transmitted infection caused by the herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2). Once a person is infected with HSV, the virus stays in the
More informationKaposi s sarcoma (KS)
Kaposi s sarcoma (KS) Summary A virus that is relatively common among gay and bisexual men called HHV-8 (human herpes virus-8) or KS herpes virus (KSHV) can cause Kaposi s sarcoma (KS). Kaposi s sarcoma
More information@2004- Beyond.360Pilates. All Rights Reserved
Supplement Guide By Sylvia Favela Copyright Notice No part of this information may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, distributing,
More informationThe search for a cure
From TreatmentUpdate 219 The search for a cure For the past several years, researchers in Canada, the U.S., Western Europe and Australia have intensified efforts to understand how HIV might be cured. Some
More informationTriumeq is the name of a pill that contains the following three anti-hiv drugs:
Triumeq Summary Triumeq is the name given to a pill containing the following three anti-hiv drugs: dolutegravir, abacavir and 3TC. Although Triumeq is generally well-tolerated, general side effects are
More informationMEASURE. MANAGE. MOTIVATE. bodyandbone MOBILE LAB DEXA BODY COMPOSITION SCAN RESTING METABOLIC RATE TEST DEXA BONE MINERAL DENSITY TEST
MEASURE. MANAGE. MOTIVATE. bodyandbone MOBILE LAB DEXA BODY COMPOSITION SCAN RESTING METABOLIC RATE TEST DEXA BONE MINERAL DENSITY TEST 4A/79 OXFORD STREET, BONDI JUNCTION NSW 2022 Body and Bone Network
More information